Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. Pfizer has ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14.  In ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

FROM sulphur burps to diarrhoea, we’re all familiar with the brutal side effects of fat jabs – but have you heard of ‘Ozempic ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

A new Canadian guideline urges lifestyle interventions for obese children but also says today's new drugs might help kids ...

Gastrointestinal problems: The side effects have been well documented - and aren’t pretty. Weight loss drugs can cause nausea ...

Meghan Trainor and husband Daryl Sabara opened up about their health journeys, which has included them both opting to take ...